[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,437,507
  • Shares Outstanding, K 53,241
  • Annual Sales, $ 49,080 K
  • Annual Income, $ -109,520 K
  • EBIT $ -178 M
  • EBITDA $ -177 M
  • 60-Month Beta -0.12
  • Price/Sales 29.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 19.54% (-0.13%)
  • Historical Volatility 92.83%
  • IV Percentile 1%
  • IV Rank 0.41%
  • IV High 296.34% on 10/23/25
  • IV Low 18.41% on 05/18/26
  • Expected Move (DTE 7) 0.00 (0.00%)
  • Put/Call Vol Ratio 75.00
  • Today's Volume 304
  • Volume Avg (30-Day) 289
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 21,106
  • Open Int (30-Day) 21,938
  • Expected Range 27.00 to 27.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 3
  • High Estimate $-0.31
  • Low Estimate $-0.37
  • Prior Year $-1.12
  • Growth Rate Est. (year over year) +69.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.68 +1.20%
on 05/12/26
27.00 unch
on 06/10/26
+0.27 (+1.01%)
since 05/08/26
3-Month
15.09 +78.93%
on 03/19/26
27.00 unch
on 06/10/26
+8.56 (+46.42%)
since 03/10/26
52-Week
9.83 +174.67%
on 06/24/25
27.00 unch
on 06/10/26
+12.79 (+90.01%)
since 06/10/25

Most Recent Stories

More News
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases

KALV : 27.00 (+0.04%)
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children...

KALV : 27.00 (+0.04%)
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 27.00 (+0.04%)
CPRX : 31.37 (+0.10%)
MDV : 18.35 (-0.43%)
GBTG : 9.36 (+0.21%)
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals...

KALV : 27.00 (+0.04%)
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 27.00 (+0.04%)
LSTA : 3.48 (-3.60%)
SILA : 30.27 (-0.07%)
THR : 61.14 (-8.49%)
Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 27.00 (+0.04%)
RMAX : 9.01 (-1.64%)
GBTG : 9.36 (+0.21%)
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

XOMA : 41.80 (+0.10%)
KALV : 27.00 (+0.04%)
RMAX : 9.01 (-1.64%)
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals...

KALV : 27.00 (+0.04%)
Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ESQ : 113.25 (+1.16%)
KALV : 27.00 (+0.04%)
TBRG : 26.07 (unch)
UNF : 275.65 (+1.12%)
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

KALV : 27.00 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 27.03
2nd Resistance Point 27.01
1st Resistance Point 27.01
Last Price 27.00
1st Support Level 26.99
2nd Support Level 26.97
3rd Support Level 26.97

See More

52-Week High 27.00
Last Price 27.00
Fibonacci 61.8% 20.44
Fibonacci 50% 18.42
Fibonacci 38.2% 16.39
52-Week Low 9.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.